Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks
Here are 10 big pharma and big biotech cancer immunotherapy stocks.
| Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks | ||||
Stock | Price Quote & Dividend | 1-Yr Price Chart | ||
| Amgen | ||||
| AstraZeneca | ||||
| Bristol-Myers Squibb | ||||
| Celgene | ||||
| Gilead Sciences | ||||
| Incyte Corporation | ||||
| Merck | ||||
| Nektar Therapeutics | ||||
| Novartis | ||||
| Pfizer | ||||
| Price and dividend data from Quandl. | ||||
To inspect the performance of the Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks portfolio, see the returns table and chart below. Portfolio values are computed using monthly closes for from Quandl. All 10 are included in the portfolio computations. The current value of the portfolio assumes that $1,000.00 was invested (total of $10,000) in each at its closing weekly price for the current date in 2008.
|
Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks - Return Results | |
| Portfolio: | Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks |
| Start date: | May-26-2008 |
| Start value: | $10,000 |
| End date: | May-26-2018 |
| End value: | $48,194 |
| Number prices | 121 |
| Minimum value occurred on Feb-28-2009 | $7,544 |
| Maximum value occurred on Mar-31-2018 | $56,441 |
| Total gain or loss (Start date to End date) | 381.94% |
| Annualized gain or loss (Start date to End date) | 17.03% |
| Total dollar value on End date of a $10,000 purchase made on Start date | $48,194 |
| Average percent return for all possible buy/sell combinations | 112.06% |
| Number returns | 7,260 |
| Number profitable returns (Winners) | 6,679 |
| Percent profitable returns | 92.00% |
| Number unprofitable returns (Losers) | 581 |
| Percent unprofitable returns | 8.00% |
| Winners to losers ratio | 11.50 |
| Stock Return Calculator | |
Related Articles
Portfolio of Big Pharmaceuticals Stocks: Cancer
Portfolio of Biotech Stocks: Cancer
Portfolio of Cancer Immunotherapy Stocks
Portfolio of Immune Checkpoint Inhibitor Stocks